Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28704622 | 0.84 | MAPT (0.60) | ALDH1A1MEN1KMT2AMAPTKDM4E | |
| SCHEMBL9726812 | 0.83 | ACHE (0.58) | ACHEALDH1A1MAPTCYP3A4TP53 | |
| SCHEMBL30100430 | 0.81 | CSNK2A1 (0.59) | ACHEALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL91954 | 0.81 | CSNK2A1 (0.59) | ACHEALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL28075439 | 0.79 | MEN1 (0.53) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL7288918 | 0.78 | STAT3 (0.54) | ALDH1A1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL30364459 | 0.78 | STAT3 (0.54) | ALDH1A1KMT2AMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3354340 | 0.77 | ACHE (0.47) | ACHEALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL3354332 | 0.77 | ACHE (0.47) | ACHEALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL1210111 | 0.77 | SRC (0.58) | ACHEALDH1A1L3MBTL1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | NYCOMED GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | 4SC AG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-7763728-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7741488-B2 | Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer | 4SC AG (DE) | 2010-06-22 | — | — | US | disclosed |
| US-20090257977-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | PEKARI KLAUS | 2009-10-15 | — | — | US | disclosed |
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | PEKARI KLAUS | 2009-10-08 | — | — | US | disclosed |
| EP-2051974-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | 4SC AG (DE) | 2009-04-29 | — | — | EP | disclosed |
| EP-2051983-A1 | NTETRAHYDROPYRIDOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | ALTANA PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| EP-1893618-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008020045-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | 4SC AG (DE) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020024-A1 | NTETRAHYDROPYRIDOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2008-02-21 | — | — | WO | disclosed |
| EP-1851230-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006125815-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006084904-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, CCAR2, BCL2 | ACHE 3754/4885ALDH1A1 566/4885L3MBTL1 2017/4885 |
| US-20090257977-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, BCL2, CCAR2 | ACHE 3472/4885ALDH1A1 632/4885L3MBTL1 2312/4885 |
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | RAB1A, RAB7A, RAB35 | ACHE 3752/4885ALDH1A1 1497/4885L3MBTL1 2961/4885 |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | ACHE 3706/4885ALDH1A1 615/4885L3MBTL1 2416/4885 |
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | BAX, BCL2, BAD | ACHE 3588/4885ALDH1A1 316/4885L3MBTL1 1169/4885 |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | MKI67, BCL2, BAX | ACHE 3783/4885ALDH1A1 576/4885L3MBTL1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.